What was the impact of the ALZA Corporation merger on Johnson & Johnson's financial statements?

The merger with ALZA Corporation, completed on June 22, 2001, was accounted for using the pooling of interests method. This means that ALZA's financial statements have been retroactively restated to be included with Johnson & Johnson's historical financial statements for comparative periods, providing a more consistent view of the combined entity's performance. The merger is expected to enhance Johnson & Johnson's drug delivery technologies and expand its pharmaceutical portfolio.

How did currency fluctuations affect Johnson & Johnson's sales in the second quarter of 2001?

The strength of the U.S. dollar relative to foreign currencies negatively impacted reported sales. For the second quarter of 2001, the stronger U.S. dollar decreased consolidated sales by 3.3%. On an operational basis, excluding currency effects, worldwide sales growth was 11.8% for the first six months and 8.8% for the quarter, indicating underlying business strength.

What are the key drivers of growth in the Pharmaceutical segment?

The Pharmaceutical segment's strong performance was driven by key products including PROCRIT/EPREX (for anemia), RISPERDAL (antipsychotic), DURAGESIC (transdermal pain patch), REMICADE (for rheumatoid arthritis and Crohn's disease), TOPAMAX (antiepileptic), and ACIPHEX/PARIET (for gastrointestinal disorders). Additionally, the FDA approval of REMINYL (galantamine hydrobromide) oral solution for Alzheimer's disease, and SPORANOX (itraconazole) for fungal infections, are significant developments.

Are there any significant legal proceedings that could materially impact Johnson & Johnson's financial position?

Johnson & Johnson is involved in several significant legal proceedings, including product liability cases related to Propulsid and antitrust allegations concerning contact lens sales. There is also a material arbitration proceeding with Amgen regarding Ortho Biotech's license rights to EPO. While the company believes it has adequate insurance and reserves, an unfavorable outcome in the Amgen arbitration could have a material adverse effect on the company's financial position, liquidity, and results of operations. Other proceedings are believed by the company not to have a material adverse effect.

JNJ 10-Q Quarterly Report Q3 FY2001 — Revenue, Net Income, EPS

Summary

Johnson & Johnson reported a strong second quarter for 2001, with consolidated sales reaching $8.34 billion, an increase of 8.8% year-over-year. This growth was primarily driven by the Pharmaceutical segment, which saw a 14.2% increase in sales, and the Medical Devices and Diagnostics segment, up 8.3%. Despite a slight decrease in the Consumer segment, the company demonstrated robust performance across its core businesses. Net earnings for the quarter were $1.48 billion, a 8.7% increase, translating to diluted EPS of $0.48. The company also completed a significant merger with ALZA Corporation, a move expected to enhance its drug delivery capabilities and product portfolio, further solidifying its market position.

Key Highlights

1Consolidated sales increased by 8.8% to $8.34 billion in Q2 2001 compared to the prior year's quarter.
2Pharmaceutical sales grew by 14.2% to $3.86 billion, driven by strong performance of key drugs like PROCRIT/EPREX and RISPERDAL.
3Medical Devices and Diagnostics segment sales rose by 8.3% to $2.79 billion, with notable contributions from Cordis, DePuy, and Ethicon products.
4Net earnings for the quarter increased by 8.7% to $1.48 billion, resulting in diluted EPS of $0.48, up from $0.44 in the prior year.
5The company completed the merger with ALZA Corporation, a strategic move to bolster its drug delivery technologies and pharmaceutical offerings.
6Total debt as a percentage of total capital decreased to 13.1% from 18.6% at the end of 2000, indicating improved financial leverage.
7The company increased its regular quarterly dividend to $0.18 per share.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Jul 1, 2001

Summary

Key Highlights

Frequently Asked Questions